Nasal spray could tame brain inflammation in progressive MS
NCT ID NCT06292923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, or a placebo for 12 weeks, and researchers will check safety and measure brain inflammation using PET scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Foralumab (a human antibody given as a nasal spray)
What this could lead to
If it works, this could point toward a new way to slow disability progression in secondary progressive MS without injections or infusions.
What could go wrong
This is an early phase 2a trial with only 54 people, so results may not confirm benefit. The main goal is safety and brain imaging changes, not yet proven to help symptoms or disability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cornell Weill Medical Center
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Buffalo
RECRUITINGBuffalo, New York, 14202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Massachusetts
RECRUITINGWorcester, Massachusetts, 01655, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale
RECRUITINGNorth Haven, Connecticut, 06473, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••